Staphylococcus aureus

Uses your system voice; voice and rate in settings.

Snapshot

≈ 11 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

on blood agar, DNase activity, clumping factor, latex agglutination, growth on mannitol-salt and Baird-Parker agar, hyaluronidase production. Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.

It is often positive for catalase and nitrate reduction and is a facultative anaerobe, meaning that it can grow without oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning.

Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA).

The bacterium is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved. An estimated 21% to 30% of the human population are long-term carriers of S.…

on blood agar, DNase activity, clumping factor, latex agglutination, growth on mannitol-salt and Baird-Parker agar, hyaluronidase production. Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.

It is often positive for catalase and nitrate reduction and is a facultative anaerobe, meaning that it can grow without oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning.

Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA).

The bacterium is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved. An estimated 21% to 30% of the human population are long-term carriers of S. aureus, which can be found as part of the normal skin microbiota, in the nostrils, and as a normal inhabitant of the lower reproductive tract of females.

S. aureus can cause a range of illnesses, from minor skin infections, such as pimples, impetigo, boils, cellulitis, folliculitis, carbuncles, scalded skin syndrome, and abscesses, to life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, bacteremia, and sepsis. It is still one of the five most common causes of hospital-acquired infections and often the cause of wound infections following surgery.

Each year, around 500,000 hospital patients in the United States contract a staphylococcal infection, chiefly by S. aureus. Up to 50,000 deaths each year in the U.S. are linked to staphylococcal infection.

Role in health

In humans, S. aureus can be present in the upper respiratory tract, gut mucosa, and skin as a member of the normal microbiota. However, because S. aureus can cause disease under certain host and environmental conditions, it is characterized as a pathobiont. In the United States, MRSA infections alone are estimated to cost the healthcare system over $3.2 billion annually.

These infections account for nearly 20,000 deaths each year in the U.S., exceeding those caused by HIV/AIDS, Parkinson's disease, and homicide. Annually, over 119,000 bloodstream infections in the U.S. are attributed to S. aureus.

S. aureus infections are ranked as one of the costliest healthcare-associated infections (HAIs), with each case averaging $23,000 to $46,000 in treatment and hospital resource utilization. On average, patients with MRSA infections experience a lengthened hospital stay of approximately 6 to 11 days, which drives up inpatient care costs.

The burden extends beyond direct healthcare expenses. Indirect costs, such as lost wages, reduced productivity, and long-term disability, can significantly amplify the overall economic toll.

Severe S. aureus infections, including bacteremia, endocarditis, and osteomyelitis, often require prolonged recovery and rehabilitation, affecting patients' ability to return to work or perform daily activities. Hospitals also invest heavily in infection control protocols to limit the spread of S. aureus, especially drug-resistant strains.

These measures include routine screening, isolation practices, use of personal protective equipment, and antibiotic stewardship programs, which collectively contribute to rising operational costs. These necessary preventative measures can raise hospital costs by tens of thousands of dollars.

Medical implant infections

Staphylococcus aureus is often found in biofilms formed on medical devices implanted in the body or on human tissue. It is commonly found with another pathogen, Candida albicans, forming multispecies biofilms. The latter is suspected to help S. aureus penetrate human tissue.

A higher mortality is linked with multispecies biofilms. Staphylococcus aureus biofilm is the predominant cause of orthopedic implant-related infections, but is also found on cardiac implants, vascular grafts, various catheters, and cosmetic surgical implants.

After implantation, the surface of these devices becomes coated with host proteins, which provide a rich surface for bacterial attachment and biofilm formation. Once the device becomes infected, it must be completely removed, since S. aureus biofilm cannot be destroyed by antibiotic treatments.

Current therapy for S. aureus biofilm-mediated infections involves surgical removal of the infected device followed by antibiotic treatment. Conventional antibiotic treatment alone is not effective in eradicating such infections. An alternative to postsurgical antibiotic treatment is using antibiotic-loaded, dissolvable calcium sulfate beads, which are implanted with the medical device.

These beads can release high doses of antibiotics at the desired site to prevent the initial infection. Novel treatments for S. aureus biofilm involving nano silver particles, bacteriophages, and plant-derived antibiotic agents are being studied. These agents have shown inhibitory effects against S. aureus embedded in biofilms.

A class of enzymes has been found to have biofilm matrix-degrading ability, thus may be used as biofilm dispersal agents in combination with antibiotics.

DNA repair

Host neutrophils cause DNA double-strand breaks in S. aureus through the production of reactive oxygen species. For infection of a host to be successful, S. aureus must survive such damages caused by the host's defenses. The two protein complex RexAB encoded by S. aureus is employed in the recombinational repair of DNA double-strand breaks.

Daptomycin is a cyclic lipopeptide antibiotic primarily used for treating Gram-positive bacterial infections, including those caused by Staphylococcus aureus. It was first approved in 2003 and is especially effective against resistant strains like methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA).

Daptomycin has a unique mechanism of action compared to other antibiotics. It aggregates in the membrane, forming an open ion channel, causing depolarization and bacterial cell death. Daptomycin is FDA-approved for treating complicated skin and soft tissue infections, bloodstream infections, and right-sided infective endocarditis caused by S. aureus.

Serum triggers a high degree of tolerance to the lipopeptide antibiotic daptomycin and several other classes of antibiotics. Serum-induced daptomycin tolerance is due to two independent mechanisms. The first one is the activation of the GraRS two-component system.

The activation is triggered by the host defense LL-37. So that, bacteria can make more peptidoglycan to make the cell wall become thicker. This can make the tolerance of bacteria.

The second one is the increase in cardiolipin abundance in the membrane. The serum-adapted bacteria can change their membrane composition. This change can reduce the binding of daptomycin to the bacteria's membrane.

Because of the high level of resistance to penicillins and because of the potential for MRSA to develop resistance to vancomycin, the U.S. Centers for Disease Control and Prevention has published guidelines for the appropriate use of vancomycin. In situations where the incidence of MRSA infections is known to be high, the attending physician may choose to use a glycopeptide antibiotic until the identity of the infecting organism is known.

After the infection is confirmed to be due to a methicillin-susceptible strain of S. aureus, treatment can be changed to flucloxacillin or even penicillin, as appropriate. Vancomycin-resistant S. aureus (VRSA) is a strain of S. aureus that has become resistant to the glycopeptides.

The first case of vancomycin-intermediate S. aureus (VISA) was reported in Japan in 1996; but the first case of S. aureus truly resistant to glycopeptide antibiotics was only reported in 2002. Three cases of VRSA infection had been reported in the United States as of 2005. At least in part the antimicrobial resistance in S. aureus can be explained by its ability to adapt.

Multiple two-component signal transduction pathways help S. aureus express genes required to survive under antimicrobial stress.

Research

As of 2024, no approved vaccine exists against S. aureus. Early clinical trials have been conducted for several vaccine candidates such as Nabi's StaphVax and PentaStaph, Intercell's / Merck's V710, VRi's SA75, and others. While some of these vaccine candidates have shown immune responses, others aggravated an infection by S. aureus.

To date, none of these candidates protects against an S. aureus infection. The development of Nabi's StaphVax was stopped in 2005 after phase III trials failed. Intercell's first V710 vaccine variant was terminated during phase II/III after higher mortality and morbidity were observed among patients who developed S. aureus infection.

Nabi's enhanced S. aureus vaccine candidate PentaStaph was sold in 2011 to GlaxoSmithKline Biologicals S.A. The current status of PentaStaph is unclear. A WHO document indicates that PentaStaph failed in the phase III trial stage. In 2010, GlaxoSmithKline started a phase 1 blind study to evaluate its GSK2392103A vaccine.

As of 2016, this vaccine is no longer under active development. Pfizer's S. aureus four-antigen vaccine SA4Ag was granted fast track designation by the U.S. Food and Drug Administration in February 2014. In 2015, Pfizer has commenced a phase 2b trial regarding the SA4Ag vaccine.

Phase 1 results published in February 20171 showed a very robust and secure immunogenicity of SA4Ag. The vaccine underwent clinical trial until June 2019, with results published in September 20201, that did not demonstrate a significant reduction in Postoperative Bloodstream Infection after Surgery.

In 2015, Novartis Vaccines and Diagnostics, a former division of Novartis and now part of GlaxoSmithKline, published promising pre-clinical results of their four-component Staphylococcus aureus vaccine, 4C-staph. In addition to vaccine development, research is being performed to develop alternative treatment options that are effective against antibiotic resistant strains including MRSA.

Examples of alternative treatments are phage therapy, antimicrobial peptides and host-directed therapy.

Standard strains

A number of standard strains of S. aureus (called "type cultures") are used in research and in laboratory testing, such as:

See also

Bundaberg tragedy, deaths of 12 children inoculated with an S. aureus-contaminated vaccine Type strain of Staphylococcus aureus at BacDive – the Bacterial Diversity Metadatabase

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369026892 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “Staphylococcus aureus” revision 1369026892 · retrieved 2026-10-20 publication date (×2) · confidence 0.95 revision URL